Evidence Hub

In Silico Comparison of SP-A and ACE2 Binding to the SARS-CoV-2 Spike Protein Using Quantum Computing

S. Aramyan, S. Sandeep, A. Haczku

TP91. TP091 EPIDEMIOLOGY AND TRANSLATIONAL ADVANCES IN SARS-COV-2, 2021

Abstract

Rationale: The pulmonary surfactant protein A (SP-A) plays an immune protective role by binding to the cell membrane of immune cells and by opsonizing infectious agents such as bacteria, fungi and viruses through glycoprotein and lipid binding domains. SARS-CoV-2 enters airway epithelial cells through its Spike glycoprotein (S protein) that binds the Angiotensin Converting Enzyme 2 (ACE2) on the cell surface. Using in silico methods we aimed to predict whether human SP-A could bind the S protein and whether this could interfere with SARS-CoV-2 - ACE2 binding. Methods: We assessed binding sites, the relative binding affinity of the interactions, and the protein chains and residues involved using ZDOCK and a novel software “Polar+” .We then compared these binding parameters between S protein - ACE2 and S protein-SP-A binding. We hypothesized that SP-A competes for the same binding site of the S protein with ACE2. We applied the “Polar+” to determine the best binding sites between the proteins.This process involved electronegativity and topologically oriented molecular pruning, calculation of electronic force-fields and electrostatic binding combined with protein-protein docking, geometric fitting and assessment of protein glycosylation sites. Results: We established the parameters of ACE2-S protein binding (left panel in figure) and found that SP-A potentially binds to the S protein with an affinity similar to that of ACE2. However, our data suggested that SP-A most likely…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free